Abstracts tagged "COVID-19"

Abstract Number: 0633 • ACR Convergence 2020
Vitamin D Serum Status in a Cohort of COVID-19 Patients
Alberto Sulli¹, Emanuele Gotelli¹, Sabrina Paolino¹, Andrea Casabella¹, Carmen Pizzorni¹, Elisa Alessandri¹, Vanessa Smith² and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genoa, Italy, ²Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium
Background/Purpose: Vitamin D serum levels have been inversely associated with risk of pulmonary infections and autoimmune inflammatory disease activity and severity [1,2]. A possible role…
Abstract Number: 1274 • ACR Convergence 2020
COVID-19 in Patients with Systemic Lupus Erythematosus
Ruth Fernandez-Ruiz¹, Mala Masson¹, Mimi Kim², Benjamin Myers³, Rebecca Haberman⁴, Jose Scher⁴, Rochelle Castillo⁴, Allison Guttmann¹, Philip Carlucci¹, Kristina Deonaraine¹, Michael Golpanian⁵, Kimberly Robins¹, Miao Chang¹, H. Michael Belmont⁶, Jill Buyon⁷, Ashira Blazer⁶, Amit Saxena⁸ and Peter Izmirly⁹, ¹New York University School of Medicine, New York, ²Albert Einstein College of Medicine, Bronx, ³Cornell University, Ithica, NY, ⁴NYU School of Medicine, New York City, ⁵New York University, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷Department of Medicine, NYU School of Medicine, New York, NY, ⁸NYU School of Medicine, New York, ⁹Department of Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) represent a unique population in considering risk for coronavirus disease 2019 (COVID-19) with biologic, genetic, demographic, clinical and…
Abstract Number: 1604 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on Rheumatology Practice: A Study in 15 Arab Countries
Nelly Ziade¹, Ihsane Hmamouchi², Lina El Kibbi³, Nizar Abdulateef⁴, Hussein Halabi⁵, Fatemah Abutiban⁶, Wafa Hamdi⁷, Manal el Rakawi⁸, Mervat Eissa⁹ and Basel Masri¹⁰, ¹Saint-Joseph University, Beirut, Lebanon, Beirut, Lebanon, ²Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, Rabat, Morocco, ³Specialized Medical Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, ⁴Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Iraq, Baghdad, Iraq, ⁵King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁶Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah hospital, State of Kuwait, Jahra, Kuwait, ⁷Department of Rheumatology, Kassab Institute of orthopedics, UR17SP04, Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia, Tunis, Tunisia, ⁸Departement of Rheumatology, Douera Hospital, Faculty of Medicine, Saad Dahlab, Blida, Algeria, Blida, Algeria, ⁹Rheumatology Department, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Jordan Hospital, Amman, Jordan, Amman, Jordan
Background/Purpose: To date, information about the impact of the Coronavirus Disease (COVID-19) pandemic on rheumatology practice and on rheumatologists is limited.The primary objective of the…
Abstract Number: 0013 • ACR Convergence 2020
Colchicine to Weather the Storm in Hospitalized Patients with COVID-19
Luigi Brunetti¹, Oumou Diawara¹, Andrew Tsai², Bonnie Firestein³, Ronald Nahass⁴, George Poiani⁵ and Naomi Schlesinger⁶, ¹Rutgers Ernest Mario School of Pharmacy, piscataway, NJ, ²Center of Excellence in Pharmaceutical Translational Research and Education, piscataway, NJ, ³Department of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, piscataway, NJ, ⁴Robert Wood Johnson University Hospital Somerset, somerset, NJ, ⁵Rutgers Robert Wood Johnson Medical School, somerset, NJ, ⁶Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) infection, is a global pandemic causing havoc. There is a knowledge gap regarding…
Abstract Number: 0430 • ACR Convergence 2020
Outcomes of Coronavirus Disease 2019 Infection Among Patients Living with Rheumatic Diseases: A Matched Cohort Study from a US Multi-Center Research Network
Kristin D'Silva¹, April Jorge¹, Na Lu², Yuqing Zhang³, Zachary Wallace⁴ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Whether patients living with systemic autoimmune rheumatic diseases (SARDs) suffer from more severe complications of Coronavirus Disease 2019 (COVID-19) infection remains unknown.Methods: We conducted…
Abstract Number: 0587 • ACR Convergence 2020
Barriers to Rheumatologic Care and Antimalarial Refills Among a Cohort of Patients with Systemic Lupus Erythematosus During the COVID-19 Pandemic
Alfredo Aguirre¹, Laura Trupin¹, Sarah Patterson², Kimberly DeQuattro², Patricia Katz³, Cristina Lanata², Stephanie Rush¹, Lindsey Criswell⁴, Maria Dall'Era⁵ and Jinoos Yazdany¹, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³University of California, San Francisco, Novato, CA, ⁴Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: The pandemic of coronavirus disease 19 (COVID-19) has led to widespread disruptions across the spectrum of healthcare. We sought to investigate barriers to medical…
Abstract Number: 0636 • ACR Convergence 2020
Rheumatology Patient Experience and Trends During the SARS-COV-2 Pandemic
Cuoghi Edens¹, Kichul Ko¹ and Kimberly Trotter¹, ¹University of Chicago, Chicago, IL
Background/Purpose: Rheumatic disease patients are counseled on the immunosuppressive aspect of their rheumatic disease treatment and their increased risk of infection. Little is known about…
Abstract Number: 1275 • ACR Convergence 2020
Unexpected Changes in Physical and Psychological Measures Among Georgia Lupus Patients During the Early Weeks of the COVID-19 Pandemic in the United States, March 30–April 21, 2020
S. Sam Lim¹, Kristina Theis², Charmayne Dunlop-Thomas¹, Gaobin Bao¹, Charles Helmick², Caroline Gordon³ and Cristina Drenkard⁴, ¹Emory University, Atlanta, GA, ²Centers for Disease Control and Prevention, Atlanta, GA, ³University of Birmingham, Birmingham, England, United Kingdom, ⁴Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA
Background/Purpose: An infectious disease outbreak can lead to negative physical and psychological consequences in the general public, as shown by the early COVID-19 pandemic, through…
Abstract Number: 1627 • ACR Convergence 2020
Phase I Trial of High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients with Mild COVID-19: A Study in the Effects of Shifting Public Opinion on Patient Enrollment
Patrick Onkka¹, Pankti Reid¹, Iazsmin Bauer Ventura¹, Brian Labadie² and Reem Jan¹, ¹University of Chicago, Chicago, IL, ²University of Chicago, Chicago
Background/Purpose: Coronavirus disease 2019 (COVID-19) was first recognized in December 2019 and quickly became a global pandemic within months. Amidst a myriad of uncertainties, early…
Abstract Number: 0014 • ACR Convergence 2020
Does the Type of Rheumatic Disease or Biologic Treatment Increase the Risk of Developing Severe COVID-19?
Fernando López-Gutierrez¹, Antía García-Fernández¹, Jesús Loarce-Martos¹, Laura Calvo-Sanz¹, Ivan Del Bosque-Granero², Veronica Garcia², Boris Blanco-Cáceres¹, Cristina Pijoan-Moratalla¹, Lourdes Villalobos-Sánchez³, Javier Bachiller-Corral¹ and Mónica Vázquez¹, ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid
Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) have an increased risk for infection related to immunosuppression secondary to their disease, treatment and comorbidities. Nonetheless recent…
Abstract Number: 0434 • ACR Convergence 2020
Changes in Mental Health During the COVID-19 Pandemic Among Individuals with Rheumatic Disease
Patricia Katz¹, Sofia Pedro², Kristin Wipfler³, Teresa Simon⁴, Yomei Shaw⁵, Adam Cornish⁶ and Kaleb Michaud⁷, ¹University of California, San Francisco, Novato, CA, ²FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ, ⁵Forward, The National Databank for Rheumatic Diseases, East Lansing, MI, ⁶FORWARD, 68134, NE, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Symptoms of both depression and anxiety are often elevated among individuals with rheumatic conditions, and stress levels may play a role in each. Depression,…
Abstract Number: 0592 • ACR Convergence 2020
A Rheumatology-Driven Protocol and Treatment Algorithm of SARS-CoV-2 Cytokine Release Syndrome and Its Associated Outcomes
Sandy Lee¹, Neha Chiruvolu², Muntarin Karim³, Patil Injean⁴, Loomee Doo⁵, Donna Jose⁶, Deepa Panikkath¹, Micah Yu⁵, Anna Lafian⁵, Wendy De La Pena⁷, Albert Chow⁸, Karina Torralba⁹, Vaneet Sandhu¹⁰, Mehrnaz Hojjati⁵, Marven Cabling⁵ and Christina Downey¹, ¹Loma Linda University Medical Center, Redlands, CA, ²UC Riverside School of Medicine, Riverside, CA, ³Loma Linda University Health System, Loma Linda, CA, ⁴LOMA LINDA UNIVERSITY MEDICAL CENTER - RHEUMATOLOGY, Redlands, CA, ⁵Loma Linda University Medical Center, LOMA LINDA, CA, ⁶Loma Linda University Medical Center, Ontario, CA, ⁷PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Loma Linda University, San Bernardino, CA, ⁹Loma Linda University School of Medicine, Redlands, CA, ¹⁰Loma Linda University, Loma Linda, CA
Background/Purpose: The newly identified SARS-CoV-2 has brought Cytokine Release Syndrome (CRS) to a level of prominence not often seen in adult medicine. Mortality rates of…
Abstract Number: 0638 • ACR Convergence 2020
Serological Evidence of SARS-CoV-2 in Symptomatic Patients Under Biological Treatment in a Rheumatology Service
Cristobal Pavez Perales¹, Samuel Leal Rodriguez², Marta De la Rubia Navarro¹, Roxana Gonzalez Mazario¹, Elena Grau Garcia³, Cristina Alcañiz Escandell³, Inmaculada Chalmeta Verdejo¹, Jorge Juan Fragio Gil¹, Luis Gonzalez Puig⁴, Jose Ivorra Cortes¹, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Francisco Miguel Ortiz Sanjuan⁵, Elvira Vicens Bernabeu² and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Rheumatology Department, HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Torrente ( Valencia), Spain, ⁵La Fe University Hospital, Valencia
Background/Purpose: In mid-March 2020, state of alarm was declared in Spain due to the novel coronavirus disease 2019 (COVID-19) pandemic. Patients with rheumatic diseases (RD)…
Abstract Number: 1279 • ACR Convergence 2020
Clinical Characteristics and Impact of the COVID-19 Pandemic in Systemic Lupus Erythematosus Patients in a Spanish Tertiary Hospital
Andrea Briones-Figueroa¹, María Jesús García-Villanueva², África Andreu Suárez¹, Marina Tortosa-Cabañas², Ana Corral-Bote², Sandra Garrote-Corral², Javier Bachiller-Corral¹ and Mónica Vázquez¹, ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Hospital Universitario Ramón y Cajal, Madrid, Spain
Background/Purpose: Data about incidence, clinical characteristics and outcome of patients with Systemic Lupus Erythematosus (SLE) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease is…
Abstract Number: 1685 • ACR Convergence 2020
Impact of the COVID-19 Pandemic Among Children with Rheumatic Diseases from Around the Globe
Jonathan Hausmann¹, Kevin Kennedy², Salman Surangiwala³, Maggie Larche⁴, Karen Durrant⁵, Rashmi Sinha⁶ and Emily Sirotich⁴, ¹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ²McMaster University, Hamilton, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Autoinflammatory Alliance, San Francisco, CA, ⁶SJIA Foundation, Cincinnati
Background/Purpose: Children with rheumatic diseases face unknown risks in the setting of the COVID-19 pandemic. These children are often immunosuppressed due to their underlying disease…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.